OA13.01 Safety and Survival Update of Tarlatamab with Anti-PD-L1 as 1L Maintenance After Chemo-IO for ES-SCLC: DeLLphi-303 Ph1b Trial
作者
K.G. Paulson,Sally C. M. Lau,M-J. Ahn,Mor Tal Moskovitz,Michael Pogorzelski,S. Haefliger,A. Parkes,S. Cho,Anahita Hamidi,Corbin G. Thompson,Martin Wermke